fructooligosaccharide and daidzein

Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person's ability to produce equol from daidzein. Equol, which is a metabolite of one of the major soybean isoflavones called daidzein, is produced in the gastrointestinal tract by certain intestinal microbiota where present. Habitual dietary patterns may alter the intestinal bacterial profile, and influence the metabolism of isoflavones and the production of equol. Fructooligosaccharides (FOS) have a prebiotic activity as well as being a dietary fibre. The purpose of the present study was to determine whether FOS supplementation increases equol production in equol producers and stimulates equol production in equol non-producers in Japanese postmenopausal women.. A soy challenge was used to assess equol-producer status prior to the start of the study in healthy postmenopausal Japanese women. The study involved 4 separate groups in randomised crossover design. First, subjects were classified as equol producers (n = 25) or non-producers (n = 18), and then they were randomly assigned to the FOS or control group. All subjects received a daily dose of 37 mg isoflavone conjugates in the capsule (21 mg aglycone form) and either FOS (5 g/day) or sucrose as control, in a randomised crossover study design. Equol -production was assessed by testing the serum and urine before and after the 2-week supplementation period.. The analyses were conducted on 34 subjects completed the study, 21 (61.8%) were classified as equol producers, and 13 (38.2%) as non-producers. Significant differences were observed in the interaction effect of time × equol state after 1 week of intervention (p = 0.006). However there were no effects after 2 weeks of intervention (p = 0.516). Finally, in both equol producers and non-producers, FOS supplementation did not affect the serum equol concentration or the urinary equol to daidzein concentration ratios.. We have reported that FOS intervention (5 g/day for 2 weeks) does not significantly modulate the capacity of intestinal microbiota to produce equol in postmenopausal Japanese women, in either equol producers or non-producers in this pilot study. Further larger investigations that explore the roles of specific intestinal microbiota in equol production will enable the establishment of dietary conditions that are required to enhance equol production.

Topics: beta-Glucans; Biomarkers; Cross-Over Studies; Dietary Supplements; Equol; Female; Glycine max; Humans; Intestinal Mucosa; Intestines; Isoflavones; Japan; Middle Aged; Oligosaccharides; Osteoporosis, Postmenopausal; Pilot Projects; Postmenopause; Prebiotics; Seeds

Red clover is an important source of isoflavones; which has been made commercially available as dietary supplements for the treatment of menopausal symptoms. Bioavailability and metabolism of these red clover isoflavones (RCI) have not been studied in detail. Fructooligosaccharides (FOS) stimulate the growth of intestinal bacteria and play an important role in the formation of certain isoflavone metabolites, such as equol and O-desmethylangolensin.. To determine the bioavailability of RCI metabolites and analyse whether FOS supplementation could influence their bioavailability.. Seventeen healthy adults were enrolled in the study carried out in two periods. In the first, compound bioavailability was determined after consumption of 80 mg of RCI (MF11RCE). In the second, a 6-day supplementation of 2×3000 mg/day of FOS was administered before isoflavone consumption.. Biochanin A and formononetin were rapidly absorbed and both reached maximum concentrations at an average of 5-7h. Demethylation was a major reaction in the metabolic pathway. Daidzein serum level peaked after about 12.6h. Supplementation with FOS led to a significant decrease in the bioavailability of daidzein, dihydroformononetin, dihydrogenistein and dihydrodaidzein. An increase in equol production was also observed which did not reach statistical significance (p>0.05).. This study is the first to provide detailed data on RCI bioavailability in humans and determine no influence of FOS yet a trend toward increased equol production. More research is warranted involving a greater sample size.

Topics: Adult; Biological Availability; Dietary Supplements; Equol; Female; Genistein; Humans; Isoflavones; Male; Oligosaccharides; Trifolium; Young Adult

Equol, a derivative of daidzein produced by enterobacteria, has greater activity as a phyto-oestrogen compared with daidzein. Difructose anhydride III (DFAIII) is a newly manufactured non-digestible disaccharide with unique fermentation properties. The present study evaluated the prebiotic effects of DFAIII on equol production and on plasma cholesterol concentrations related to the changes in equol production. We compared plasma equol concentrations at 10.00 and 18.00 hours and faecal isoflavone excretion in three groups of seven rats (male Wistar-ST strain, 6 weeks old) fed a basal diet or a DFAIII or fructooligosaccharide (15 g/kg diet) diet containing 1 g soya isoflavones/kg diet for 20 d. Equol concentrations in the DFAIII group were higher than in the control and fructooligosaccharides groups, especially in the later phase of the light period (18.00 hours) throughout the experiment. Daizein and genistein concentrations did not change between the diet groups. The faecal ratios of equol:daidzein were very high in all groups, but the ratios were higher in the DFAIII group than the control and fructooligosaccharide groups on day 3, and this tendency continued throughout the experiment. On day 20, the plasma total cholesterol concentration was lowest in the DFAIII group. Additionally, the cholesterol concentrations were inversely correlated to plasma equol concentration in all the rats. In conclusion, DFAIII efficiently enhanced plasma equol concentrations, which may be associated with an increase in equol production and a decrease in equol degradation by enterobacteria. Higher plasma equol concentrations may contribute to the hypocholesterolaemic effect of DFAIII feeding.

Topics: Animals; Body Weight; Cecum; Cholesterol; Diet; Dietary Supplements; Disaccharides; Equol; Feces; Genistein; Isoflavones; Male; Oligosaccharides; Phytoestrogens; Rats; Rats, Wistar

Only about one third of humans possess a microbiota capable of transforming the dietary isoflavone daidzein into equol. Little is known about the dietary and physiological factors determining this ecological feature. In this study, the in vitro metabolism of daidzein by faecal samples from four human individuals was investigated. One culture produced the metabolites dihydrodaidzein and O-desmethylangolensin, another produced dihydrodaidzein and equol. From the latter, a stable and transferable mixed culture transforming daidzein into equol was obtained. Molecular fingerprinting analysis (denaturing gradient gel electrophoresis) showed the presence of four bacterial species of which only the first three strains could be brought into pure culture. These strains were identified as Lactobacillus mucosae EPI2, Enterococcus faecium EPI1 and Finegoldia magna EPI3, and did not produce equol in pure culture. The fourth species was tentatively identified as Veillonella sp strain EP. It was found that hydrogen gas in particular, but also butyrate and propionate, which are all colonic fermentation products from poorly digestible carbohydrates, stimulated equol production by the mixed culture. However, when fructo-oligosaccharides were added, equol production was inhibited. Furthermore, the equol-producing capacity of the isolated culture was maintained upon its addition to a faecal culture originating from a non-equol-producing individual.

Topics: Bacteria; Butyrates; DNA Fingerprinting; DNA, Bacterial; DNA, Ribosomal; Enterococcus faecium; Equol; Feces; Genes, rRNA; Humans; Hydrogen; Isoflavones; Lactobacillus; Molecular Sequence Data; Oligosaccharides; Phylogeny; Propionates; RNA, Bacterial; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Veillonella

Fructooligosaccharides (FOS) stimulate the growth of bifidobacteria, which cleave isoflavone conjugates to yield the corresponding aglycones and metabolites. In a previous study, FOS modified the absorption and enterohepatic recirculation of isoflavones in rats. In the present study, we determined the effect of the combination of dietary FOS and isoflavone conjugates on bone mass in ovariectomized (OVX) and surgical control mice. After undergoing OVX or sham operation, female ddY mice (8 wk old, n = 64) were randomly assigned to four groups: a purified control diet (AIN-93G) group, a FOS diet (AIN-93G + 5% FOS) group, an isoflavone diet (AIN-93G + 0.2% isoflavone conjugates) group, or a FOS and isoflavone diet (AIN-93G + 5% FOS + 0.2% isoflavone conjugates) group. After 6 wk, the mice were killed and the blood and femora were sampled immediately. In OVX mice, both isoflavone conjugates and FOS prevented femoral bone loss. An additive effect of dietary isoflavone conjugates and FOS was observed by dual-energy X-ray absorptiometry in the distal part of the femur and in trabecular bone, by peripheral quantitative computed tomography. Moreover, FOS increased cecal beta-glucosidase activity and equol production from daidzein in both OVX and surgical control mice fed isoflavone conjugates. These results suggest that FOS increase the bioavailability of isoflavones, leading to cooperative effects in the prevention of osteopenia in OVX mice.

Topics: Absorptiometry, Photon; Animals; beta-Glucosidase; Bone Density; Calcium; Cecum; Chromans; Diet; Drug Synergism; Equol; Estrogens, Non-Steroidal; Female; Femur; Genistein; Isoflavones; Magnesium; Mice; Oligosaccharides; Osmolar Concentration; Ovariectomy; Phosphorus; Tomography, X-Ray Computed

The influence of dietary fructooligosaccharides (FOS) on bioavailability of genistein and daidzein in rats was estimated by measuring their concentrations in plasma collected from three different veins and in urine after a single intragastric administration of isoflavone conjugates. Sprague-Dawley male rats (6 wk old, n = 22) were fed a purified control (AIN-93G) diet or a FOS diet (AIN-93G + 5% FOS) for 7 d. A single dose of soy isoflavone conjugates, i.e., 8.5 mg as genistein and 33 mg as daidzein/kg body, was administered via a stomach tube at d 5. Blood samples were collected after administration via catheters in the portal and central veins and by puncture of the tail vein. The isoflavones in plasma and urine were analyzed by time-resolved fluoroimmunoassay. The genistein concentration in the portal blood increased rapidly, reaching a peak of 3.5 micromol/L in both groups at 1 h after administration. The concentrations in the central and tail venous blood were approximately half of those in the portal blood. In the FOS-fed group, both genistein and daidzein remained detectable at 24 and 48 h in the tail venous plasma. The urinary excretion of both isoflavones in the 24- to 48-h period after administration was significantly higher in the FOS-fed group than in the control group. The difference between the portal and central veins indicated hepatic uptake, probably leading to conjugation of aglycones and excretion into bile. FOS modified the absorption and enterohepatic recirculation of isoflavones.

Topics: Animals; Biological Availability; Catheterization; Estrogens, Non-Steroidal; Fluoroimmunoassay; Genistein; Intestinal Absorption; Isoflavones; Liver; Male; Oligosaccharides; Rats; Rats, Sprague-Dawley; Time Factors